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Summary 16 
The apicomplexan protozoan parasites include the causative agents of animal and human 17 
diseases ranging from malaria (Plasmodium spp.) to toxoplasmosis (Toxoplasma gondii). The 18 
complex life cycle of T. gondii is regulated by a unique family of calcium-dependent protein 19 
kinases (CDPKs) that have become the target of intensive efforts to develop new 20 
therapeutics. In this review, we will summarize structure-based strategies and recent 21 
successes in the pursuit of specific and selective inhibitors of T. gondii CDPK1. 22 
  23 
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Introduction 24 
The phylum of Apicomplexa contains approximately 6000 unicellular, eukaryotic parasites 25 
including Plasmodium spp, the causative agent of Malaria, and Toxoplasma gondii, 26 
responsible for toxoplasmosis in many important farm animals and humans (Sato, 2011). 27 
Morphologically, all members of the apicomplexan family share am distinctive apical 28 
complex and unique apical-localised organelles such as the apicoplast, is a non-29 
photosynthetic relict plastid found in both, Plasmodium spp. and T. gondii  (McFadden & 30 
Yeh, 2017). These parasites employ complex life cycles including both sexual and asexual 31 
reproduction, and often involving multiple hosts. T. gondii, first described in 1908 and often 32 
regarded as one of the most successful apicomplexan parasites, represents the key model 33 
organism of the phylum (Weiss & Dubey, 2009, Szabo & Finney, 2017, Dubey, 2008). Its 34 
primary hosts are members of the Felidae (cats) family and all other warm-blooded animals 35 
including humans, are intermediate hosts. It is estimated that up to one third of the human 36 
population is infected with T. gondii and thus are potential carriers. Although the infection is 37 
usually asymptotic in healthy individuals it can cause severe congenital disease during 38 
pregnancy (Kaye, 2011), and lead to life-threatening infections in immuno-compromised 39 
patients including those suffering from HIV, having received an organ transplant or receiving 40 
cancer chemotherapy treatment (Flegr et al., 2014). Current toxoplasmosis treatment 41 
options are limited to a handful of antimicrobials such as sulphonamides, folic acid 42 
derivatives and certain macrolide antibiotics. However, these drugs often show limited 43 
efficacy and are associated with significant side effects (Alday & Doggett, 2017). 44 
Furthermore, there are no treatments available to target tissue cysts, the persistent form in 45 
which the parasite evades the host immune system, and to eradicate persistent T. gondii 46 
infections (Opsteegh et al., 2015). Therefore, new drug targets and therapies are urgently 47 
needed. In addition to high-throughput screening approaches (Norcliffe et al., 2014), 48 
structure-based methods in close combination with medicinal chemistry and biophysical 49 
and biological validation have become powerful tools in the search of new drugs against 50 
infectious diseases (Hol, 2015, Groftehauge et al., 2015, Muller, 2017, Verlinde et al., 2009). 51 
The role of Calcium-dependent protein kinases 52 
Calcium is an essential element for almost all eukaryotic organisms with wide-ranging 53 
biological functions. In Toxoplasma, Ca2+-ions play a key roles in cell signalling and in 54 
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pathogen-host interaction including cell invasion, motility of the parasite within the host 55 
and differentiation during the parasites complex life cycle  (Irvine, 1986, Nagamune et al., 56 
2008, Lourido & Moreno, 2015). Calcium dependent protein kinases (CDPKs) are 57 
serine/threonine kinases that are only found in plants and protists including ciliates and 58 
apicomplexan parasites. Importantly, they provide the mechanistic link between calcium 59 
signalling and motility, differentiation and invasion (Tzen et al., 2007, Billker et al., 2009). 60 
These key roles of CDPKs have been proven in a range of knock-out studies in various 61 
species and underline their potential as targets for novel therapeutics (Long et al., 2016) 62 
(Wang et al., 2016). So far, at least twelve different CDPKs have been putatively identified in 63 
the T. gondii alone ranging from 583 (CDPK1) to more than 2000 (CDPK7, CDPK8 (Morlon-64 
Guyot et al., 2014)) amino acids in length with sequence identities ranging from 51% (CDPK1 65 
and CDPK3 (Treeck et al., 2014)) to lower than 10% in the conserved regions (Table 1) (Hui 66 
et al., 2015).  CDPKs are members of the Calmodulin/Calcium kinase (CaM) family and hence 67 
they share an N-terminal kinase domain (KD) linked via a junctional domain to a series of C-68 
terminal Calcium-binding motifs. However, as evidenced by their sequence variation, 69 
different members of the CDPK family have vastly different substrates and biological 70 
functions in T. gondii biology. CDPK1 which is the most comprehensively studied member of 71 
the family, has been shown to be required for the microneme secretion at the apical 72 
complex and parasite proliferation (Lourido et al., 2010, Child et al., 2017).  73 
Due to its key role in infection and because the mammalian hosts do not possess any 74 
representative of the same kinase family, CDPK1 from Plasmodium Cryptosporidium and 75 
Toxoplasma spp. has attracted significant attention as a potential novel drug target (Donald 76 
et al., 2006, Sugi et al., 2010, Larson et al., 2012). Here we will review strategies and recent 77 
results in the discovery, design and potency of inhibitors of the CDPK1 from T. gondii 78 
(TgCDPK1). 79 
Activation of TgCDPK1 by Calcium 80 
Detailed structural studies began in 2010 when the crystal structures of both the auto-81 
inhibited and the Ca2+-activated forms of TgCDPK1 were published (Ojo et al., 2010, 82 
Wernimont et al., 2010). These structures revealed the expected canonical KD in similar 83 
overall conformations, however, the Ca2+--binding domain (also designated CPDK activating 84 
domain or CAD) adopted two vastly different conformations and orientations (Figure 1a and 85 
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1b). In its inactive state the CAD (shown in raspberry red) adopts an elongated form 86 
reminiscent of apo-calmodulin starting with a long helix followed by the first Ca2+-binding 87 
motif (EF-hands) which is connected via another long helix to the second C-terminal EF-88 
hand. The first long helix is responsible for the auto-inhibitory effect by blocking the 89 
substrate binding site and providing a basic lysine residue to bind a cluster of conserved 90 
acidic residues. Calcium binding leads to a dramatic rearrangement and refolding of the 91 
protein chain (Figure 1b) (Wernimont et al., 2010). The entire regulatory domain is shifted 92 
to the other side of the protein hence liberating the active site of the kinase domain as 93 
shown in Figure 2. In addition, the regulatory calcium-binding domain is collapsed so that 94 
the two long helices are no longer arranged in an anti-parallel fashion but are partially 95 
unwound and interwoven to form a more globular overall shape. These structural changes 96 
are reminiscent to the calcium-bound structure of calmodulin (Kursula, 2014).  However, the 97 
reorientation and structural changes observed in TgCDPK1 are more profound, presumably 98 
due to the long linker region between the two Ca2+-binding EF-hands. 99 
Comparison with human kinases 100 
Historically characterising (protozoan) kinases as potential drug targets and developing 101 
selective inhibitors has been considered challenging due to the fact that the overall protein 102 
fold and the active sites are structurally well conserved in all kinases. The structural 103 
similarities are obvious when comparing the crystal structures of the kinase domain of 104 
CDPK1 from T. gondii with Calcium/Calmodulin (CaM) dependent-kinase II from H. sapiens 105 
(HsCaMKII) (Figure 3a). These two proteins, which share a sequence identity of 106 
approximately 42% over 264 residues of the kinase domain display the same canonical 107 
kinase fold and superimpose with an overall root mean square deviation of approximately 108 
1.5 Å. Note that the loop over the adenosine triphosphate (ATP) binding site adopts a very 109 
different conformation presumably due to an induced fit of binding of two very different 110 
ligands. TgCDPK1 is bound to the ATP analogue ANP while HsCaMKII is bound to a 111 
comparatively small inhibitor. More importantly there are significant differences in the ATP 112 
binding site, specifically an unusually small residue (glycine) close to the adenine binding 113 
position. This residue, glycine 128 is also termed  the gatekeeper residue. Almost all 114 
mammalian kinases possess a large residue, a phenylalanine in HsCaMKII for example, in 115 
this position. Hence, the protozoan kinases feature an enlarged ATP binding site with a 116 
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hydrophobic pocket that can be exploited for structure-based drug design. This key 117 
structural difference in the binding pocket is shown in the surface representation where the 118 
ATP-analogue is shown as stick representation (Figure 3a). The additional space at the end 119 
of the pocket below the surface of the gatekeeper residue glycine 128 in magenta is clearly 120 
visible. 121 
Development of specific TgCDPK1 inhibitors 122 
Soon after the importance of this enzyme and the structural differences were established 123 
two groups started to develop selective TgCDPK1 inhibitors. Initial compounds were based 124 
on known inhibitors previously developed for yeast kinases featuring amino acids with small 125 
side chains at the gatekeeper position. Importantly, these known kinase inhibitors, termed 126 
bumped kinase inhibitors (BKI) have been shown to be inactive against mammalian kinases 127 
(Hanke et al., 1996). Generally, BKIs are based on the planar pyrazolo[3,4-d]pyrimidin-4-128 
amine substituted with a bulky hydrophobic group on the C3 position (Bishop et al., 1998). 129 
The first example of a BKI with a sub-micromolar IC50 is 1-(1-methylethyl)-3-(naphthalen-1-130 
ylmethyl)-1H-pyrazolo[3,4-d] pyrimidin-4-amine. The co-crystal structure shows that the 131 
naphtalen-1-ylmethyl- moiety perfectly fills the hydrophobic pocket created by the small 132 
gatekeeper residue Gly128 and lined by methionine and leucine residues, and one lysine 133 
residue (Figure 4a,c). The chemically closely related 1-tert-butyl-3-naphthalen-2-yl-1H-134 
pyrazolo[3,4-d]pyrimidin-4-amine (Figure 4b,d) adopts a similar conformation with the bulky 135 
aromatic substituent at the C3 position occupying the space next to the gatekeeper residue. 136 
Critically for the subsequent drug development was the fact that these and related BKIs 137 
reduced T. gondii proliferation significantly (Ojo et al., 2010, Sugi et al., 2010). These results 138 
sparked extensive medicinal chemistry efforts where a large number of compounds based 139 
on the BKI scaffold (4-amino-1H-pyrazole[3,4-d]pyrimidine) were synthesized and tested 140 
resulting in optimized TgCDPK1 inhibitors. A number of compounds exhibited sub- or low-141 
nanomolar for IC50 values and high activity in parasite growth models (EC50 in the low- and 142 
sub micromolar range) while retaining specificity when compared to mammalian kinases 143 
(Lourido et al., 2013) (Zhang et al., 2014) (Moine et al., 2015). In addition to the 144 
pyrazolopyrimidine (PP) scaffolds, acylbenzimidazole and 5-aminopyrzazole-4-carboxamide 145 
based compounds shown in Figure 5 with similar properties have been successfully 146 
developed (Zhang et al., 2012, Zhang et al., 2014, Huang et al., 2015). While the initial BKIs 147 
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showed excellent potency in vitro and in vivo they also exhibited significant hERG (human 148 
Ether-a go-go-go Related Gene) inhibition thus posing potential cardiotoxicity (Doggett et 149 
al., 2014). Further extensive medicinal chemistry efforts finally led to the current lead of 150 
TgCDPK1 inhibitors, (1-{4-amino-3-[2-(cyclopropyloxy)quinolin-6-yl]-1H-pyrazolo[3,4-151 
d]pyrimidin-1-yl}-2-methylpropan-2-ol) that combined high activity and selectivity with 152 
favourable pharmacokinetic properties and low hERG activity (Vidadala et al., 2016). Note 153 
that the copounds is bound to the protein via H-bonds of the pyrimidin ring to the main 154 
chain of the proitein, while the hydrophobic cyclopropyloxyquinolin moiety forms a large 155 
number of hydrophobic interactions. Taken together, the structure based approaches of 156 
drug development applied to TgCDPK1 has led to three different series of compounds with 157 
high inhibitory activity, good pharmacokinetic parameters and promising efficacy in murine 158 
models. 159 
Future challenges 160 
Over the last five years there has been significant progress in the development of selective 161 
inhibitors of one of the key CDPKs from T. gondii taking advantage of a series of high-162 
resolution crystal structures. Although the most promising compounds show high efficacy in 163 
murine models more work needs to be done to increase solubility and bio-availability in 164 
order to proceed to clinical trials. While most of the previous work has focused on T. gondii, 165 
further work is currently underway to investigate inhibitors of CDPK1 from Cryptosporidium 166 
and Plasmodium spp. (Gaji et al., 2014, Green et al., 2015, Crowther et al., 2016). In 167 
addition, more works needs to be done to understand the role of the other members of the 168 
Apicomplexan CDPK family. In this regard, the development of CRISPR/Cas9 technology in 169 
members of Apicomplexan family (Shen et al., 2014, Vinayak et al., 2015) facilitated the 170 
detailed analysis of the biological function of CDPK family members (Long et al., 2016).  171 
 172 
 173 
  174 
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Table 1: The protein sequence identities between the twelve full length putati8ve CDPKs of 287 
T. gondii, rounded to the nearest whole number, derived from a multiple sequence 288 
alignment (MSA) generated using Clustal Omega (Sievers et al., 2011). 289 
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CDPK2B 30% 34% 37%  33% 16% 25% 36% 13% 8% 8% 26% 
CDPK3 51% 25% 27% 33%  14% 25% 30% 12% 7% 7% 25% 
CDPK4 14% 14% 20% 16% 14%  14% 15% 17% 11% 9% 14% 
CDPK4A 24% 21% 20% 25% 25% 14%  21% 8% 6% 6% 18% 
CDPK5 25% 32% 32% 36% 30% 15% 21%  13% 7% 8% 26% 
CDPK6 9% 14% 15% 13% 12% 17% 8% 13%  16% 8% 12% 
CDPK7 7% 7% 9% 8% 7% 11% 6% 7% 16%  8% 7% 
CDPK8 6% 9% 9% 8% 7% 9% 6% 8% 8% 8%  7% 
CDPK9 22% 26% 24% 26% 25% 14% 18% 26% 12% 7% 7%  
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Figure Legends 293 
Figure 1: Ribbon representation of the crystal structure of CDPK1 from T. gondii with the 294 
kinase domain depicted in cyan, the regulatory domain in raspberry red and the non-295 
hydrolysable ligand ANP in stick representation (a) CDPK1 in its inactive auto-inhibited state 296 
(PDB code: 3KU2) (Wernimont et al., 2010) (b) CDPK1 in its calcium-bound activated state 297 
with the Ca2+-ions shown as green spheres (PDB code: 3HX4) (Wernimont et al., 2010). 298 
Figure 2: Ribbon diagram of the least-squares superposition of the inactive and active forms 299 
of CDPK1 with the kinase domains shown in different shades of cyan, the regulatory domain 300 
in shades of red, respectively. Only the kinase domain was used to calculate the 301 
transformation matrix which was then applied to the entire protein chain. 302 
Figure 3: (a) Least squares superposition of the kinase domain of TgCDPK1 (depicted in 303 
cyan) in its active form (PDB: 3HX4) with HsCaMKII bound to an inhibitor (PDB: 2VZ6) 304 
(shown in green) (Rellos et al., 2010). The non-hydrolysable ATP analogue bound in CDPK1 is 305 
presented as ball-and-stick representation to highlight the ATP binding site. (b) Surface 306 
representation of TgCDPK1 viewing into the binding pocket with color coding according to 307 
atom type (oxygen in red, nitrogen in blue, carbon in grey). The surface of Gly128 308 
(gatekeeper residue) is shown in magenta highlighting the additional space in the binding 309 
pocket of TgCDPK1. 310 
Figure 4: Close-up of BKIs bound to TgCDPK1 in the ATP binding site. The gatekeeper residue 311 
Gly128 is depicted in magenta, key hydrophobic residue of the binding site in grey (a) 1-(1-312 
methylethyl)-3-(naphthalen-1-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine shown in ball-313 
and-stick representation (PDB: 3i7b) (b) 1-tert-butyl-3-naphthalen-2-yl-1H-pyrazolo[3,4-314 
d]pyrimidin-4-amine (PDB:3i7c) (Ojo et al., 2010). (c) (d) chemical structures of the ligands. 315 
Figure 5: The three different scaffolds for TgCDPK1 inhibitors (a) Pyrazolpyrimidines (b) 316 
Acylbenzimidazoles (c) 5-aminopyrazole-4-carboxamide 317 
Figure 6: Crystal structure of (1-{4-amino-3-[2-(cyclopropyloxy)quinolin-6-yl]-1H-318 
pyrazolo[3,4-d]pyrimidin-1-yl}-2-methylpropan-2-ol) shown in stick representation bound to 319 
for TgCDPK1 shown in cartoon representation with selected residues depicted in sticks 320 
(Vidadala et al., 2016). 321 
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Figure 1: Ribbon representation of the crystal structure of CDPK1 from T. gondii with the kinase domain 
depicted in cyan, the regulatory domain in raspberry red and the non-hydrolysable ligand ANP in stick 
representation (a) CDPK1 in its inactive auto-inhibited state (PDB code: 3KU2) (Wernimont et al., 2010) (b) 
CDPK1 in its calcium-bound activated state with the Ca2+-ions shown as green spheres (PDB code: 3HX4) 
(Wernimont et al., 2010).  
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Figure 2: Ribbon diagram of the least-squares superposition of the inactive and active forms of CDPK1 with 
the kinase domains shown in different shades of cyan, the regulatory domain in shades of red, respectively. 
Only the kinase domain was used to calculate the transformation matrix which was then applied to the 
entire protein chain.  
 
80x63mm (300 x 300 DPI)  
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Figure 3: (a) Least squares superposition of the kinase domain of TgCDPK1 (depicted in cyan) in its active 
form (PDB: 3HX4) with HsCaMKII bound to an inhibitor (PDB: 2VZ6) (shown in green) (Rellos et al., 2010). 
The non-hydrolysable ATP analogue bound in CDPK1 is presented as ball-and-stick representation to 
highlight the ATP binding site. (b) Surface representation of TgCDPK1 viewing into the binding pocket with 
color coding according to atom type (oxygen in red, nitrogen in blue, carbon in grey). The surface of Gly128 
(gatekeeper residue) is shown in magenta highlighting the additional space in the binding pocket of 
TgCDPK1.  
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Figure 4: Close-up of BKIs bound to TgCDPK1 in the ATP binding site. The gatekeeper residue Gly128 is 
depicted in magenta, key hydrophobic residue of the binding site in grey (a) 1-(1-methylethyl)-3-
(naphthalen-1-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine shown in ball-and-stick representation (PDB: 
3i7b) (b) 1-tert-butyl-3-naphthalen-2-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (PDB:3i7c) (Ojo et al., 
2010). (c) (d) chemical structures of the ligands.  
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Figure 5: The three different scaffolds for TgCDPK1 inhibitors (a) Pyrazolpyrimidines (b) Acylbenzimidazoles 
(c) 5-aminopyrazole-4-carboxamide  
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Figure 6: Crystal structure of (1-{4-amino-3-[2-(cyclopropyloxy)quinolin-6-yl]-1H-pyrazolo[3,4-d]pyrimidin-
1-yl}-2-methylpropan-2-ol) shown in stick representation bound to for TgCDPK1 shown in cartoon 
representation with selected residues depicted in sticks (Vidadala et al., 2016).  
 
80x54mm (300 x 300 DPI)  
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Abstract 
The apicomplexan protozoan parasites include the causative agents of animal and human 
diseases ranging from malaria (Plasmodium spp.) to toxoplasmosis (Toxoplasma gondii). The 
complex life cycle of T. gondii is regulated by a unique family of calcium-dependent protein 
kinases (CDPKs) that have become the target of intensive efforts to develop new 
therapeutics. In this review, we will summarize structure-based strategies and recent 
successes in the pursuit of specific and selective inhibitors of T. gondii CDPK1. 
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Introduction 
The phylum of Apicomplexa contains approximately 6000 unicellular, eukaryotic parasites 
including Plasmodium spp., the causative agent of Malaria, and Toxoplasma gondii, 
responsible for toxoplasmosis in many important farm animals and humans (Sato, 2011). 
Morphologically, all members of the apicomplexan family share a distinctive apical complex, 
together with species dependent apical-localised organelles. The apicoplast, for example, a 
non-photosynthetic plastid is found in both, Plasmodium spp. and T. gondii  (McFadden & 
Yeh, 2017). These parasites employ complex life cycles including both sexual and asexual 
reproduction, and often involving multiple hosts. T. gondii, first described in 1908 and often 
regarded as one of the most successful apicomplexan parasites, represents the key model 
organism of the phylum (Weiss & Dubey, 2009, Szabo & Finney, 2017, Dubey, 2008). Its 
primary hosts are members of the Felidae (cats) family while all other warm-blooded 
animals, including humans, are intermediate hosts. It is estimated that up to one third of 
the human population is infected with T. gondii and thus are potential carriers. Although the 
infection is usually asymptotic in healthy individuals it can cause severe congenital disease 
during pregnancy (Kaye, 2011), and lead to life-threatening infections in immuno-
compromised patients including those suffering from HIV, receiving an organ transplant or 
undergoing cancer chemotherapy treatment (Flegr et al., 2014). Current toxoplasmosis 
treatment options are limited to a handful of antimicrobials such as sulphonamides, folic 
acid derivatives and certain macrolide antibiotics. However, these drugs often show limited 
efficacy and are associated with significant side effects (Alday & Doggett, 2017). 
Furthermore, there are no treatments available to target tissue cysts, the persistent form in 
which the parasite evades the host immune system, and to eradicate persistent T. gondii 
infections (Opsteegh et al., 2015). Therefore, new drug targets and novel therapies are 
urgently needed. In addition to high-throughput screening approaches (Norcliffe et al., 
2014), structure-based methods in close combination with medicinal chemistry and 
biophysical and biological validation have become powerful tools in the search of new drugs 
and treatments (Hol, 2015, Groftehauge et al., 2015, Muller, 2017, Verlinde et al., 2009, 
Hunter, 2009). 
The role of calcium-dependent protein kinases 
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In T. gondii Ca2+-ions play key roles in cell signalling and in pathogen-host interactions 
including cell invasion, motility of the parasite within the host and differentiation during the 
parasites complex life cycle  (Irvine, 1986, Nagamune et al., 2008, Lourido & Moreno, 2015). 
Calcium dependent protein kinases (CDPKs) are a family of serine/threonine kinases that are 
only found in plants and protists including ciliates and apicomplexan parasites. Importantly, 
CDPKs provide the mechanistic link between calcium signalling and motility, differentiation 
and invasion (Tzen et al., 2007, Billker et al., 2009). These key roles of CDPKs have been 
proven through a range of knock-out studies in various species and underline the potential 
of CDPKs as targets for novel therapeutics (Long et al., 2016). CDPKs are members of the 
Calmodulin/Calcium kinase (CaM) family. They share an N-terminal kinase domain (KD) 
linked via a junctional domain to a series of C-terminal Calcium-binding motifs. 
In T. gondii at least twelve different CDPKs have been putatively identified ranging in size 
from 537 (CDPK3) to more than 2000 amino acids (CDPK7, CDPK80) (Morlon-Guyot et al., 
2014). The shared sequence identities range from 51% (CDPK1 and CDPK3) (Treeck et al., 
2014) to lower than 10% (Table 1) (Hui et al., 2015). As evidenced by their vast variation in 
length and sequence, members of the CDPK family act upon dissimilar substrates and fulfil 
different functions in T. gondii biology. Recent knock-out studies using CRISPR-Cas9 indicate 
that CDPK4, CDPK5, CDPK6, CDPK8, and CDPK9, respectively, have no effect on virulence 
and on normal growth (Wang et al., 2016), however, knock-down studies have shown that 
CDPK7 is crucial for survival due to a critical role in parasite division (Morlon-Guyot et al., 
2014). More detailed studies have been performed on the smaller family members. CDPK3 
with 537 amino acids has been implicated in motility and host cell egress (McCoy et al., 
2017). CDPK2 (711 amino acids) has been shown to act as key regulator of amylopectin 
metabolism(Uboldi et al., 2015). The loss of CDPK2 results in the build-up of amylum with 
fatal consequences for T. gondii in its chronic stage. Importantly, this family member 
contains an N-terminal carbohydrate-binding domain that may offer new opportunities for 
drug design (Uboldi et al., 2015).  CDPK1 (582 amino acids), which is mainly located in the 
cytosol, has been shown to be required for the microneme secretion at the apical complex 
and parasite proliferation. The molecular mechanism, however, remains elusive (Lourido et 
al., 2010, Child et al., 2017).  Due to their key roles in infection CDPK1 from Plasmodium, 
Cryptosporidium and Toxoplasma spp. have attracted significant attention as a potential 
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novel drug target (Donald et al., 2006, Sugi et al., 2010, Larson et al., 2012). Here we will 
review strategies and recent results in the discovery, design and potency of inhibitors 
targeting the kinase domain of CDPK1 from T. gondii (TgCDPK1). 
Activation of TgCDPK1 by Calcium 
The mechanism of activation and inhibition was unravelled in 2010 when the crystal 
structures of both the auto-inhibited and the Ca2+-activated forms of TgCDPK1 were 
published (Ojo et al., 2010, Wernimont et al., 2010). These structures revealed the expected 
kinase domain (KD) in similar overall conformations, however, the Ca2+--binding domain 
(also designated CPDK activating domain or CAD) adopted two vastly different 
conformations and orientations (Figure 1). In its inactive state the CAD (shown in raspberry 
red) adopts an elongated form reminiscent of apo-calmodulin starting with a long helix 
followed by the first Ca2+-binding motifs (EF-hands) which is connected via another long 
helix to the second pair of C-terminal EF-hands (Figure 1a). The first long helix has been 
suggested to be responsible for the auto-inhibitory effect by blocking the substrate binding 
site and providing a basic lysine residue to bind a cluster of conserved acidic residues. 
However, this may not be the only mechanism of deactivation as it has more recently been 
shown that removal of the regulatory domain alone does not lead to an active kinase 
domain (Ingram et al., 2015).  The CAD domain activated by Ca2+-binding appears to be 
required to maintain the KD in its active conformation. Calcium binding leads to a dramatic 
rearrangement and refolding of the protein chain (Figure 1b) (Wernimont et al., 2010). The 
entire regulatory domain is shifted to the other side of the protein hence liberating the 
active site of the kinase domain as shown in Figure 1c. In addition, the regulatory calcium-
binding domain is collapsed so that the two long helices are no longer arranged in an anti-
parallel fashion but are partially unwound and interwoven to form a more globular overall 
shape. These structural changes are reminiscent to the calcium-bound structure of 
calmodulin (Kursula, 2014). 
Comparison with human kinases 
Historically, characterising (protozoan) kinases as potential drug targets and developing 
selective inhibitors has been considered challenging due to the fact that the overall protein 
fold and the active sites are structurally well conserved (Scapin, 2002). The structural 
similarities are obvious when comparing the crystal structures of the kinase domain of 
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TgCDPK1 with the Calcium/Calmodulin (CaM) dependent-kinase II from H. sapiens 
(HsCaMKII) (Figure 2a) (Rellos et al., 2010). These two proteins, which share a sequence 
identity of approximately 42% over 264 residues of the kinase domain, display the same 
canonical kinase fold and superimpose with an overall root mean square deviation of 
approximately 1.5 Å. Note that the loop over the adenosine triphosphate (ATP) binding site 
adopts a very different conformation presumably due to an induced fit of binding of two 
very different ligands. TgCDPK1 is bound to the ATP analogue ANP (Figure 2a) while 
HsCaMKII is bound to a comparatively small inhibitor. More importantly there are significant 
differences in the ATP binding site, specifically an unusually small residue (glycine) close to 
the adenine binding position. This residue, Gly128 is also termed the gatekeeper residue. 
Almost all mammalian kinases possess a large residue, a phenylalanine in HsCaMKII for 
example, in this position. Hence, CDPK1 feature an enlarged ATP binding site with a 
hydrophobic pocket that can be exploited for structure-based drug design. This key 
structural difference in the binding pocket is shown in the surface representation where the 
ATP-analogue is shown as stick representation (Figure 2b). The additional space at the end 
of the pocket below the surface of the gatekeeper residue Gly 128 in magenta is clearly 
visible. 
Development of specific TgCDPK1 inhibitors 
Soon after the structural differences were identified between TgCDPK1 and the mammalian 
homologues two groups started to develop selective TgCDPK1 inhibitors (Wernimont et al., 
2010, Ojo et al., 2010). Initial compounds were based on known inhibitors previously 
developed for yeast kinases featuring amino acids with small side chains at the gatekeeper 
position. Importantly, these known kinase inhibitors, termed bumped kinase inhibitors (BKI) 
have been shown to be inactive against mammalian kinases (Hanke et al., 1996). Generally, 
BKIs are based on the planar pyrazolo[3,4-d]pyrimidin-4-amine substituted with a bulky 
hydrophobic group on the C3 position (Bishop et al., 1998). The first example of a BKI with a 
sub-µmolar IC50 is 1-(1-methylethyl)-3-(naphthalen-1-ylmethyl)-1H-pyrazolo[3,4-d] 
pyrimidin-4-amine. The co-crystal structure of TgCDPK1 shows that the naphtalen-1-
ylmethyl- moiety fills the hydrophobic pocket created by the small gatekeeper residue 
Gly128 and lined by methionine and leucine residues, and one lysine residue (Figure 3a,b). 
The chemically closely related 1-tert-butyl-3-naphthalen-2-yl-1H-pyrazolo[3,4-d]pyrimidin-4-
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amine (Figure 3c,d) adopts a similar conformation with the bulky aromatic substituent at 
the C3 position occupying the space next to the gatekeeper residue. Critically for the 
subsequent drug development was the fact that these and related BKIs reduced T. gondii 
proliferation significantly (Ojo et al., 2010, Sugi et al., 2010). These results sparked extensive 
medicinal chemistry efforts where a large number of compounds based on the BKI scaffold 
(4-amino-1H-pyrazole[3,4-d]pyrimidine) were synthesized and tested resulting in optimized 
TgCDPK1 inhibitors. A number of compounds exhibited sub- or low-nanomolar IC50 values 
and high activity in parasite growth models (EC50 in the low- and sub-µmolar range) while 
retaining specificity when compared to mammalian kinases (Lourido et al., 2013) (Zhang et 
al., 2014) (Moine et al., 2015). In addition to the pyrazolopyrimidine (PP) scaffolds, 
acylbenzimidazole and 5-aminopyrzazole-4-carboxamide based compounds have been 
shown to have similar properties (Figure 4) (Zhang et al., 2012, Zhang et al., 2014, Huang et 
al., 2015). While the initial BKIs showed excellent potency in vitro and in vivo they also 
exhibited significant hERG (human Ether-Related Gene) inhibition thus posing potential 
cardiotoxicity (Doggett et al., 2014). Further extensive medicinal chemistry efforts finally led 
to the current lead TgCDPK1 inhibitor, (1-{4-amino-3-[2-(cyclopropyloxy)quinolin-6-yl]-1H-
pyrazolo[3,4-d]pyrimidin-1-yl}-2-methylpropan-2-ol) that combines high activity and 
selectivity with favourable pharmacokinetic properties and low hERG activity (Vidadala et 
al., 2016). Note that the compound is bound to the protein via H-bonds of the pyrimidin ring 
to the main chain, while the hydrophobic cyclopropyloxy-quinoline moiety forms a large 
number of hydrophobic interactions (Figure 5). Taken together, the structure based 
approaches of drug development applied to TgCDPK1 has led to three different series of 
compounds with high inhibitory activity, good pharmacokinetic parameters and promising 
efficacy in murine models. 
Future challenges 
Over the last five years there has been significant progress in the development of selective 
inhibitors of one of the key CDPKs from T. gondii achieved by taking advantage of a series of 
high-resolution crystal structures. While most of the previous work has focused on T. gondii, 
further work is currently underway to investigate inhibitors of CDPK1 from Cryptosporidium 
and Plasmodium spp. (Gaji et al., 2014, Green et al., 2015, Crowther et al., 2016).  Although 
the most promising TgCDPK1 inhibitors show high efficacy in murine models more work 
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needs to be done to increase solubility and bio-availability in order to proceed to clinical 
trials. Furthermore, current lead compounds only target the ATP binding site of TgCDPK1. 
However, allosteric kinase inhibitors and modulators have shown enormous potential to 
target specific kinases and could be further exploited (Fang et al., 2013). Additional binding 
sites in less conserved regions such as the carbohydrate binding site recently discovered in 
TgCDPK2 can serve as starting points for the development of new inhibitors (Uboldi et al., 
2015). Clearly, more works needs to be done to understand the role of the other members 
of the Apicomplexan CDPK family. In this regard, the recent development of CRISPR/Cas9 
technology to modify the genes of members of the Apicomplexan family (Shen et al., 2014, 
Vinayak et al., 2015) will greatly facilitate the detailed analysis of the biological function of 
CDPK family members (Long et al., 2016, Wang et al., 2016). 
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Figure Legends 
Figure 1: Ribbon representation of the crystal structure of CDPK1 from T. gondii with the 
kinase domain depicted in cyan, the regulatory domain in raspberry red (a) CDPK1 in its 
inactive auto-inhibited state (PDB code: 3KU2) (Wernimont et al., 2010) (b) CDPK1 in its 
calcium-bound, activated state with the Ca2+-ions shown as green spheres and the non-
hydrolysable ligand ANP in stick representation (PDB code: 3HX4) (Wernimont et al., 2010), 
(c) Ribbon diagram of the least-squares superposition of the inactive and active forms of 
TgCDPK1 with the kinase domains shown in cyan (active) and blue (inactive), the regulatory 
domain in shades of red, respectively. Only the kinase domain was used to calculate the 
transformation matrix which was then applied to the entire protein chain. 
Figure 2: (a) Least squares superposition of the kinase domain of TgCDPK1 (depicted in 
cyan) in its active form with HsCaMKII bound to an inhibitor (PDB: 2VZ6) (shown in orange) 
(Rellos et al., 2010). The non-hydrolysable ATP analogue bound in TgCDPK1 is presented as 
ball-and-stick representation to highlight the substrate binding site. (b) Surface 
representation of TgCDPK1 viewing into the binding pocket with color coding according to 
atom type (oxygen in red, nitrogen in blue, carbon in grey). The surface of Gly128 
(gatekeeper residue) is shown in magenta at the top of the figure highlighting the additional 
space in the binding pocket. 
Figure 3: Close-up of BKIs bound to TgCDPK1 in the ATP binding site. The gatekeeper residue 
Gly128 is depicted in magenta, key hydrophobic residue of the binding site are labelled and 
shown in grey (a) 1-(1-methylethyl)-3-(naphthalen-1-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-
4-amine shown in ball-and-stick representation (PDB: 3i7b) (b) chemical structure of the 
ligand (c) 1-tert-butyl-3-naphthalen-2-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (PDB:3i7c) 
(Ojo et al., 2010)  (d) chemical structure of the ligand 
Figure 4: The three different scaffolds for TgCDPK1 inhibitors (a) Pyrazolpyrimidines (b) 
Acylbenzimidazoles (c) 5-aminopyrazole-4-carboxamide 
Figure 5: Crystal structure of (1-{4-amino-3-[2-(cyclopropyloxy)quinolin-6-yl]-1H-
pyrazolo[3,4-d]pyrimidin-1-yl}-2-methylpropan-2-ol) shown in stick representation bound to 
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for TgCDPK1 shown in cartoon representation with selected residues depicted in sticks 
(Vidadala et al., 2016). 
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Table 1: The protein sequence identities between the 12 putative CDPKs of T. gondii, 
rounded to the nearest whole number, derived from a multiple sequence alignment (MSA) 
generated using Clustal Omega (Sievers et al., 2011). 
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CDPK2A 23% 34%  37% 27% 20% 20% 32% 15% 9% 9% 24% 
CDPK2B 30% 34% 37%  33% 16% 25% 36% 13% 8% 8% 26% 
CDPK3 51% 25% 27% 33%  14% 25% 30% 12% 7% 7% 25% 
CDPK4 14% 14% 20% 16% 14%  14% 15% 17% 11% 9% 14% 
CDPK4A 24% 21% 20% 25% 25% 14%  21% 8% 6% 6% 18% 
CDPK5 25% 32% 32% 36% 30% 15% 21%  13% 7% 8% 26% 
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Figure 4 
 (a) Pyrazolpyrimidines 
 
 
 
 
 (b) Acylbenzimidazoles  
 
 
 
 
 
 
(c) 5-aminopyrazole-4-carboxamide 
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Figure 5. 
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Ribbon representation of the crystal structure of CDPK1 from T. gondii with the kinase domain depicted in 
cyan, the regulatory domain in raspberry red (a) CDPK1 in its inactive auto-inhibited state (PDB code: 
3KU2) (Wernimont et al., 2010) (b) CDPK1 in its calcium-bound, activated state with the Ca2+-ions shown 
as green spheres and the non-hydrolysable ligand ANP in stick representation (PDB code: 3HX4) (Wernimont 
et al., 2010), (c) Ribbon diagram of the least-squares superposition of the inactive and active forms of 
TgCDPK1 with the kinase domains shown in cyan (active) and blue (inactive), the regulatory domain in 
shades of red, respectively. Only the kinase domain was used to calculate the transformation matrix which 
was then applied to the entire protein chain.  
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: (a) Least squares superposition of the kinase domain of TgCDPK1 (depicted in cyan) in its active form with 
HsCaMKII bound to an inhibitor (PDB: 2VZ6) (shown in orange) (Rellos et al., 2010). The non-hydrolysable 
ATP analogue bound in TgCDPK1 is presented as ball-and-stick representation to highlight the substrate 
binding site. (b) Surface representation of TgCDPK1 viewing into the binding pocket with color coding 
according to atom type (oxygen in red, nitrogen in blue, carbon in grey). The surface of Gly128 (gatekeeper 
residue) is shown in magenta at the top of the figure highlighting the additional space in the binding pocket. 
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Close-up of BKIs bound to TgCDPK1 in the ATP binding site. The gatekeeper residue Gly128 is depicted in 
magenta, key hydrophobic residue of the binding site are labelled and shown in grey (a) 1-(1-methylethyl)-
3-(naphthalen-1-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine shown in ball-and-stick representation 
(PDB: 3i7b) (b) chemical structure of the ligand (c) 1-tert-butyl-3-naphthalen-2-yl-1H-pyrazolo[3,4-
d]pyrimidin-4-amine (PDB:3i7c) (Ojo et al., 2010)  (d) chemical structure of the ligand  
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The three different scaffolds for TgCDPK1 inhibitors (a) Pyrazolpyrimidines (b) Acylbenzimidazoles (c) 5-
aminopyrazole-4-carboxamide  
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Crystal structure of (1-{4-amino-3-[2-(cyclopropyloxy)quinolin-6-yl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}-2-
methylpropan-2-ol) shown in stick representation bound to for TgCDPK1 shown in cartoon representation 
with selected residues depicted in sticks (Vidadala et al., 2016).  
 
 
390x281mm (72 x 72 DPI)  
 
 
Page 60 of 60
Cambridge University Press
Parasitology
